PTEN and non-small cell lung carcinoma: Moreover, loss of PTEN expression causes strong resistance to EGFR-targeting drugs, such as gefitinib or erlotinib, by preventing the suppression of Akt activation and promoting EGR1 translocation in NSCLC cells [2, 53, 54].